vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Grindr Inc. (GRND). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $126.0M, roughly 1.3× Grindr Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 29.0%). Over the past eight quarters, Grindr Inc.'s revenue compounded faster (29.3% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Grindr is a location-based social networking and online hookup application for LGBTQ people.
ESPR vs GRND — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $126.0M |
| Net Profit | — | $20.3M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 24.9% |
| Net Margin | — | 16.1% |
| Revenue YoY | 143.7% | 29.0% |
| Net Profit YoY | — | 116.4% |
| EPS (diluted) | $0.32 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $126.0M | ||
| Q3 25 | $87.3M | $115.8M | ||
| Q2 25 | $82.4M | $104.2M | ||
| Q1 25 | $65.0M | $93.9M | ||
| Q4 24 | $69.1M | $97.6M | ||
| Q3 24 | $51.6M | $89.3M | ||
| Q2 24 | $73.8M | $82.3M | ||
| Q1 24 | $137.7M | $75.3M |
| Q4 25 | — | $20.3M | ||
| Q3 25 | $-31.3M | $30.8M | ||
| Q2 25 | $-12.7M | $16.6M | ||
| Q1 25 | $-40.5M | $27.0M | ||
| Q4 24 | — | $-123.9M | ||
| Q3 24 | $-29.5M | $24.7M | ||
| Q2 24 | $-61.9M | $-22.4M | ||
| Q1 24 | $61.0M | $-9.4M |
| Q4 25 | 50.6% | 24.9% | ||
| Q3 25 | -11.4% | 39.1% | ||
| Q2 25 | 8.6% | 23.4% | ||
| Q1 25 | -34.0% | 27.0% | ||
| Q4 24 | -6.4% | 20.9% | ||
| Q3 24 | -31.0% | 31.8% | ||
| Q2 24 | 3.5% | 29.8% | ||
| Q1 24 | 52.5% | 25.6% |
| Q4 25 | — | 16.1% | ||
| Q3 25 | -35.9% | 26.6% | ||
| Q2 25 | -15.4% | 16.0% | ||
| Q1 25 | -62.2% | 28.8% | ||
| Q4 24 | — | -126.9% | ||
| Q3 24 | -57.2% | 27.6% | ||
| Q2 24 | -83.9% | -27.2% | ||
| Q1 24 | 44.3% | -12.5% |
| Q4 25 | $0.32 | $0.10 | ||
| Q3 25 | $-0.16 | $0.16 | ||
| Q2 25 | $-0.06 | $0.08 | ||
| Q1 25 | $-0.21 | $0.09 | ||
| Q4 24 | $-0.14 | $-0.65 | ||
| Q3 24 | $-0.15 | $0.09 | ||
| Q2 24 | $-0.33 | $-0.13 | ||
| Q1 24 | $0.34 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $87.0M |
| Total DebtLower is stronger | — | $395.9M |
| Stockholders' EquityBook value | $-302.0M | $47.0M |
| Total Assets | $465.9M | $531.0M |
| Debt / EquityLower = less leverage | — | 8.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $87.0M | ||
| Q3 25 | $92.4M | $6.3M | ||
| Q2 25 | $86.1M | $120.8M | ||
| Q1 25 | $114.6M | $255.9M | ||
| Q4 24 | $144.8M | $59.2M | ||
| Q3 24 | $144.7M | $39.1M | ||
| Q2 24 | $189.3M | $16.3M | ||
| Q1 24 | $226.6M | $21.5M |
| Q4 25 | — | $395.9M | ||
| Q3 25 | — | $279.9M | ||
| Q2 25 | — | $283.5M | ||
| Q1 25 | — | $287.0M | ||
| Q4 24 | — | $290.6M | ||
| Q3 24 | — | $294.1M | ||
| Q2 24 | — | $297.7M | ||
| Q1 24 | — | $315.0M |
| Q4 25 | $-302.0M | $47.0M | ||
| Q3 25 | $-451.4M | $71.0M | ||
| Q2 25 | $-433.5M | $187.7M | ||
| Q1 25 | $-426.2M | $319.8M | ||
| Q4 24 | $-388.7M | $-131.6M | ||
| Q3 24 | $-370.2M | $-13.4M | ||
| Q2 24 | $-344.2M | $-41.7M | ||
| Q1 24 | $-294.3M | $-22.0M |
| Q4 25 | $465.9M | $531.0M | ||
| Q3 25 | $364.0M | $439.2M | ||
| Q2 25 | $347.1M | $547.6M | ||
| Q1 25 | $324.0M | $679.4M | ||
| Q4 24 | $343.8M | $479.1M | ||
| Q3 24 | $314.1M | $456.3M | ||
| Q2 24 | $352.3M | $435.0M | ||
| Q1 24 | $373.1M | $437.7M |
| Q4 25 | — | 8.42× | ||
| Q3 25 | — | 3.94× | ||
| Q2 25 | — | 1.51× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $24.8M |
| Free Cash FlowOCF − Capex | — | $24.5M |
| FCF MarginFCF / Revenue | — | 19.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $140.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $24.8M | ||
| Q3 25 | $-4.3M | $55.4M | ||
| Q2 25 | $-31.4M | $37.5M | ||
| Q1 25 | $-22.6M | $23.8M | ||
| Q4 24 | $-35.0M | $29.5M | ||
| Q3 24 | $-35.3M | $29.1M | ||
| Q2 24 | $-7.2M | $15.8M | ||
| Q1 24 | $53.8M | $20.4M |
| Q4 25 | — | $24.5M | ||
| Q3 25 | — | $55.2M | ||
| Q2 25 | — | $37.3M | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | — | $29.3M | ||
| Q3 24 | $-35.5M | $28.8M | ||
| Q2 24 | $-7.3M | $15.7M | ||
| Q1 24 | $53.8M | $20.3M |
| Q4 25 | — | 19.5% | ||
| Q3 25 | — | 47.7% | ||
| Q2 25 | — | 35.8% | ||
| Q1 25 | — | 25.2% | ||
| Q4 24 | — | 30.0% | ||
| Q3 24 | -68.7% | 32.2% | ||
| Q2 24 | -9.9% | 19.0% | ||
| Q1 24 | 39.0% | 26.9% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.3% | 0.4% | ||
| Q2 24 | 0.1% | 0.2% | ||
| Q1 24 | 0.1% | 0.3% |
| Q4 25 | — | 1.22× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | — | 0.88× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GRND
| License And Service | $102.9M | 82% |
| Advertising | $23.1M | 18% |
